Evotec (XTRA:EVT) Valuation Check As CFO Transition Draws Fresh Attention To The Stock

Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE.

Evotec (XTRA:EVT) is back in focus after announcing that CFO Paul Hitchin will step down on 30 April 2026. Experienced finance executive Claire Hinshelwood is set to assume the role from 1 May.

See our latest analysis for Evotec.

The CFO succession news comes as the stock trades at €5.345, with a 30 day share price return of 18.70%, a 1 year total shareholder return of 28.54%, and a 5 year total shareholder return of 84.27%. This suggests that recent momentum contrasts with a much weaker longer term picture.

If this kind of leadership change has you reviewing your portfolio, it can help to compare other pharmaceutical and biotech groups using a healthcare AI focused screener such as 125 healthcare AI stocks.

With the stock up over the past month but showing weaker multi year returns and trading below analyst and intrinsic value estimates, you might ask: is Evotec undervalued today, or is the market already pricing in future growth?

Most Popular Narrative: 22% Undervalued

Evotec's most followed narrative points to a fair value of €6.83 per share versus the last close at €5.35, putting the current price well below that estimate and framing recent gains as only part of the story.

Evotec's expansion and deepening of large pharma partnerships, as evidenced by the rapid growth of its Just, Evotec Biologics (JEB) business with three major pharma clients and a move to an asset lighter, technology focused licensing model, are expected to drive recurring, higher margin revenue streams, supporting revenue growth and boosting net margins.

Read the complete narrative.

Curious what sits behind that valuation gap? The narrative leans on compounding revenue, a swing from losses to profits and a richer profit margin profile. The key assumptions are all quantified, from top line growth to future earnings and the multiple investors might accept.

Result: Fair Value of €6.83 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, the story could change quickly if biotech funding stays weak for longer or if any major pharma partner pulls back on contracts or volumes.

Find out about the key risks to this Evotec narrative.

Next Steps

With mixed sentiment around Evotec's upside and risks, this is a good moment to review the numbers yourself and decide where you stand, starting with the 2 key rewards and 1 important warning sign

Looking for more investment ideas?

If Evotec has you thinking about where to put your next euro, do not stop here. Broaden your watchlist with focused sets of stocks that fit clear criteria.

Story Continues

Target potential mispricings by scanning 236 high quality undervalued stocks that combine quality fundamentals with prices that may not fully reflect their underlying metrics. Strengthen your income stream by reviewing 488 dividend fortresses built around higher yielding companies where payouts are a central part of the return profile. Prioritise resilience by checking 300 resilient stocks with low risk scores that score well on stability, so you are not relying on just one stock to manage volatility.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include EVT.DE.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]

View Comments